Dupilumab for treating moderate to severe prurigo nodularis (TA955)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 March 2024
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 December 2023
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 August 2021
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 November 2024
Rezafungin for untreated invasive candidiasis TS ID 10768Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC